Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303628 · ClinicalTrials.gov registry record · Phase 3
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT00303628 is a Phase 3 study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 355 participants.
The verdict
NCT00303628, a Phase 3 study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab in treating rectal cancer. This randomized phase III trial is studying combination chemotherapy to see how well it works with or without bevacizumab in treating patients who have had surgery for stage II or stage III rectal cancer.
Interventions
- DRUG bevacizumab
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2006-05-11 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303628
The ClinicalTrials.gov registry entry for NCT00303628 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bevacizumab is the first listed.
NCT00303628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303628 about?
NCT00303628 is a clinical study titled "Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer". Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the...
What is the current status of trial NCT00303628?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2006-05-11. Estimated completion is 2019-02-11.
What interventions are being tested in trial NCT00303628?
The interventions under investigation include: bevacizumab (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG).
Who is sponsoring clinical trial NCT00303628?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.